Targeted Drug Shows Promise in Common Form of Lymphoma 
Preliminary results from two early-phase clinical trials suggest that the investigational drug ibrutinib may benefit some patients with an aggressive type of non-Hodgkin lymphoma (NHL). In the trials, some patients with diffuse large B-cell lymphoma (DLBCL) who did not respond to standard therapies, or who had stopped responding to these treatments, experienced complete or substantial tumor shrinkage after treatment with ibrutinib. The treatment was well tolerated, with only minor side effects.
Dr. Louis Staudt of NCI’s Center for Cancer Research (CCR), who co-led both trials, presented the findings April 1 at the 2012 American Association for Cancer Research annual meeting in Chicago. Read more > >
Drawbacks of Adding MRI to Mammography Plus Ultrasound May Outweigh Benefits
Supplemental screening increased cancer detection and false-positive resultsUltrasound-Guided Breast-Conserving Surgery May Reduce Need for Further Surgeries
Technique aids complete removal of cancerous tissue while sparing healthy tissueAnal HPV Infections and Precancerous Lesions Are Common in Men Who Have Sex with Men
More information is needed before screening can be recommendedOlaparib Delays Progression of Ovarian Cancer after Initial Treatment
As maintenance therapy, PARP inhibitor prolongs remission but not overall survivalTransplant Recipients at Higher Risk of Aggressive Form of Lymphoma
Study advances understanding of risk factors for non-Hodgkin lymphoma subtypeSome Melanoma Cells May Use the Body’s Immune Response to Escape Destruction
B7-H1 protein may block immune cells in up to 40 percent of patients with melanomaAlso in the Journals: Methylation Levels in HPV DNA May Indicate Risk for Cervical Precancer
COMMENTARY
A Conversation with Dr. Bert Vogelstein about Whole-Genome Sequencing to Predict Cancer Risk
The director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and an investigator with the Howard Hughes Medical Institute explains the potential and the limitations of whole-genome sequencing.IN DEPTH
U.S. Cancer Deaths Continue Steady Decline
Annual Report to the Nation highlights growing cancer risk of excess weight and insufficient physical activityDrugs Target Epigenetic Changes to Reprogram Cancer Cells
Lab study, early trials show methylation-blocking drugs can produce strong antitumor responsesFeatured Clinical Trial: Virus Therapy for Extensive-Stage Small Cell Lung Cancer
Will Seneca Valley virus therapy improve progression-free survival of patients with aggressive lung cancer?
UPDATES
Legislative Update
- Senate Appropriations Hearing Highlights NCI’s Provocative Questions Project
FDA Update
- FDA Takes Action under the Tobacco Control Act of 2009
Notes
- Cyber-Seminar will Explore Measuring the Health of a Community
- Dr. John Potter to Deliver First Schatzkin Lecture in Nutritional Epidemiology
No hay comentarios:
Publicar un comentario